Am J Leuk Res | Volume 6, Issue 1 | Case Report | Open Access
Donatella V*, Annalisa S, Giorgio R, Carmelo T, Al Sayyad S, Mauro C, Francesco T, Giuseppina C, Mila F, Giuseppe I, Francesco M, Maria Grazia MCD, Oliva Bianca Maria BIE, Cristina G, Veronica L, Francesca L, Angela P, Bruno M, Massimo R, Domenico Q and Bruno
Department of Hematology, Great Metropolitan Hospital, Bianchi-Melacrino-Morelli, Italy
*Correspondance to: Vincelli Donatella
Fulltext PDFHematological malignancies represent an important part of all blood disorders. Many hematological cancers feature chronic course, requiring repeated cycles of treatment and determining long-term sequelae. In the last few years, there have been remarkable developments in the diagnosis and treatment of these cancers, and their prognoses markedly improved. This article is descriptive in nature. It shows how the pattern of VMP therapy (velcade, dexamethasone and melphalan and revlimid) alternating with imatinib controlled myeloma and chronic myeloid leukemia. Great efficacy of adding daratumumab and dexamethasone to lenalidomide treatment. This is a case report of a male adult of 78 years of age with monoclonal gammopathy progressing to multiple myeloma, chronic lymphocytic leukemia that did not require treatment, and chronic myeloid leukemia.
Chronic Lymphocytic leukemia; Chronic Myeloid leukemia; Multiple myeloma; Malignancies; Hemoglobin
Donatella V, Annalisa S, Giorgio R, Carmelo T, Al Sayyad S, Mauro C, et al. A Patient with Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia and Multiple Myeloma. Am J Leuk Res. 2023; 6(1): 1028.